Breast Cancer Research
The NSABP Foundation Inc. focuses on clinical research in early breast cancer, with particular attention to triple-negative breast cancer and treatment strategies used before and after surgery.
- Triple-negative breast cancer
- Early-stage breast cancer
- Neoadjuvant therapy
- Adjuvant therapy
Its research activity is centered on improving outcomes in patients with aggressive breast cancer subtypes through oncology-focused clinical evaluation.
Immuno-Oncology
The sponsor is involved in studies examining immune checkpoint inhibition in combination with standard chemotherapy for breast cancer.
- Atezolizumab
- Checkpoint blockade
- Immune-based cancer treatment
- Combination systemic therapy
These interests place emphasis on integrating immunotherapy into treatment pathways for patients with triple-negative breast cancer.
Systemic Anticancer Treatment
Research activities include the use of multi-agent chemotherapy regimens for patients with breast cancer, particularly treatments built around paclitaxel, carboplatin, and anthracycline-based therapy.
- Paclitaxel
- Carboplatin
- Anthracycline-based therapy
- Combined modality treatment
The clinical focus remains on optimizing systemic treatment approaches for patients with localized but high-risk disease.
Multicenter Oncology Collaboration
The sponsor supports research conducted across a broad network of collaborating research sites, reflecting active involvement in coordinated breast cancer studies across North America and other participating regions.
- Multisite clinical research
- Collaborative oncology networks
- Cross-border trial activity
- Breast cancer study coordination
This networked structure supports research in oncology with a strong emphasis on patient access to specialized breast cancer trials.
